Home  /   Products  /   Antiallergic  /   Levocetirizine (Elcet) 5 mg – [14 tablets]

Levocetirizine (Elcet) 5 mg – [14 tablets]


Anti-allergic agent – h1-histamine receptor blocker

SKU: 63396 Category:


Levocetirizine (Elcet) Pharmacodynamics
Levocetirizine is the active substance of Elcet – it is R-enantiomer of cetirizine, a powerful and selective histamine antagonist, which blocks H1-histamine receptors.
Levocetirizine affects the histamine-dependent stage of allergic reactions, as well as reduces the migration of eosinophils, reduces vascular permeability, and limits the release of inflammatory mediators.
Levocetirizine prevents the development and facilitates the course of allergic reactions, it has antiexudative, antipruritic action, it has practically no anticholinergic and antiserotonin action. In therapeutic doses it has practically no sedative effect.
– Treatment of symptoms of year-round (persistent) and seasonal (intermittent) allergic rhinitis and allergic conjunctivitis, such as itching, sneezing, nasal congestion, rhinorrhea, lacrimation, conjunctival hyperemia.
– Pollinosis (hay fever).
– Urticaria, including chronic idiopathic urticaria.
– Other allergic dermatoses accompanied by itching and rashes.
Hypersensitivity to the active substance, cetirizine, hydroxyzine, any piperazine derivative or any other excipient of the drug.
Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Terminal stage of renal failure (creatinine clearance < 10 ml/min).
Children under 6 years of age (due to limited data on safety and efficacy).
Dosage and administration
  • Film-coated tablets are taken orally, swallowed as whole with a meal or on an empty stomach with a small amount of water.
  • Adults and children over 6 years of age: daily dose is 5 mg (1 tablet) once.
  • As levocetirizine is excreted by kidneys, in patients with renal failure and elderly patients the dose should be adjusted according to the degree of renal failure.
  • Patients with mild renal impairment (creatinine clearance 50-79 ml/min) do not require dose adjustment.
  • In patients with moderate renal impairment (creatinine clearance from 30 to 49 ml/min) the recommended dose is 5 mg every other day.
  • In patients with severe renal impairment (creatinine clearance less than
  • 30 ml/min), the recommended dose is 5 mg once every 3 days.
  • In patients with renal and hepatic impairment the dosing is carried out according to the above scheme.
  • In patients with liver function abnormality only dosage regimen correction is not required.
  • Duration of drug administration:
  • When treating seasonal (intermittent) rhinitis (presence of symptoms less than 4 days per week or their total duration less than 4 weeks) the duration of treatment depends on the duration of symptoms; treatment may be discontinued when symptoms disappear and resumed when symptoms appear.
  • When treating year-round (persistent) allergic rhinitis (presence of symptoms more than 4 days per week and their total duration of more than 4 weeks), treatment may continue for the duration of allergen exposure.
  • There is clinical experience with continuous use of levocetirizine in the dosage form of film-coated tablets 5 mg in adult patients for up to 6 months.
  • Tell your doctor if you are taking or have recently taken other medicines.
  • If you forget to take Levocetirizine (Elcet), do not take a double dose to make up for a missed dose, take the next dose at the usual time.